General Information of Drug (ID: DMQURWZ)

Drug Name
Indole-based analog 14 Drug Info
Synonyms PMID27410995-Compound-Figure3a
Cross-matching ID
PubChem CID
53246690
TTD Drug ID
DMQURWZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27410995-Compound-Figure3j DMJRZLB N. A. N. A. Patented [1]
Pyrrolo[2,3-d]pyrimidine derivative 35 DMXU08A N. A. N. A. Patented [1]
BI-D1870 DMK3SAF Chronic lymphocytic leukaemia 2A82.0 Preclinical [2]
PMID22765894C8h DMH5RFU Discovery agent N.A. Investigative [3]
PMID22564207C25b DMBMYKQ Discovery agent N.A. Investigative [4]
BIX 02565 DMNAX1Q Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ribosomal protein S6 kinase alpha-3 (RSK3) TTUM2ZR KS6A3_HUMAN Inhibitor [1]

References

1 Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
2 BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38.
3 The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
4 Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
5 Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity. Bioorg Med Chem Lett. 2012 Jan 1;22(1):738-42.